Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiativeToxicological sciences, 2014-12, Vol.142 (2), p.427-435 [Peer Reviewed Journal]The Author 2014. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. ;ISSN: 1096-6080 ;EISSN: 1096-0929 ;DOI: 10.1093/toxsci/kfu198 ;PMID: 25246669Full text available |
|
2 |
Material Type: Article
|
A product of independent beta probabilities dose escalation design for dual-agent phase I trialsStatistics in medicine, 2015-04, Vol.34 (8), p.1261-1276 [Peer Reviewed Journal]2015 The Authors. Published by John Wiley & Sons Ltd. ;2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. ;2015 The Authors. Published by John Wiley & Sons Ltd. 2015 ;ISSN: 0277-6715 ;EISSN: 1097-0258 ;DOI: 10.1002/sim.6434 ;PMID: 25630638 ;CODEN: SMEDDAFull text available |
|
3 |
Material Type: Article
|
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced MelanomaJournal of clinical oncology, 2017-03, Vol.35 (7), p.785-792 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2015.66.1389 ;PMID: 28068177Full text available |
|
4 |
Material Type: Article
|
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatmentJournal of clinical oncology, 2015-01, Vol.33 (3), p.278-284 [Peer Reviewed Journal]2014 by American Society of Clinical Oncology 2014 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2014.58.2635 ;PMID: 25512456Full text available |
|
5 |
Material Type: Article
|
The COVID-19 vaccine development landscapeNature reviews. Drug discovery, 2020-05, Vol.19 (5), p.305-306 [Peer Reviewed Journal]COPYRIGHT 2020 Nature Publishing Group ;Nature 2020. ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/d41573-020-00073-5 ;PMID: 32273591Full text available |
|
6 |
Material Type: Article
|
Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trialsBritish journal of cancer, 2020-11, Vol.123 (10), p.1496-1501 [Peer Reviewed Journal]The Author(s), under exclusive licence to Cancer Research UK 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s), under exclusive licence to Cancer Research UK 2020 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-020-01033-x ;PMID: 32868897Full text available |
|
7 |
Material Type: Article
|
Embracing model-based designs for dose-finding trialsBritish journal of cancer, 2017-07, Vol.117 (3), p.332-339 [Peer Reviewed Journal]Copyright Nature Publishing Group Jul 25, 2017 ;Copyright © 2017 The Author(s) 2017 The Author(s) ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/bjc.2017.186 ;PMID: 28664918Full text available |
|
8 |
Material Type: Article
|
FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLCClinical cancer research, 2022-04, Vol.28 (8), p.1482-1486 [Peer Reviewed Journal]2021 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-21-3074 ;PMID: 34903582Full text available |
|
9 |
Material Type: Article
|
Commentary on the EMA Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal productsBritish journal of clinical pharmacology, 2018-07, Vol.84 (7), p.1401-1409 [Peer Reviewed Journal]2018 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. ;2018 The British Pharmacological Society ;ISSN: 0306-5251 ;EISSN: 1365-2125 ;DOI: 10.1111/bcp.13550 ;PMID: 29451320Full text available |
|
10 |
Material Type: Article
|
Phase I–II clinical trial design: a state-of-the-art paradigm for dose findingAnnals of oncology, 2018-03, Vol.29 (3), p.694-699 [Peer Reviewed Journal]2017 THE AUTHORS ;The Author(s) 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2017 ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdx795 ;PMID: 29267863Full text available |
|
11 |
Material Type: Article
|
Genome-editing Technologies for Gene and Cell TherapyMolecular therapy, 2016-03, Vol.24 (3), p.430-446 [Peer Reviewed Journal]2016 Official journal of the American Society of Gene & Cell Therapy ;Copyright Nature Publishing Group Mar 2016 ;Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy 2016 Official journal of the American Society of Gene & Cell Therapy ;ISSN: 1525-0016 ;EISSN: 1525-0024 ;DOI: 10.1038/mt.2016.10 ;PMID: 26755333Full text available |
|
12 |
Material Type: Article
|
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1Clinical cancer research, 2017-04, Vol.23 (8), p.1920-1928 [Peer Reviewed Journal]2016 American Association for Cancer Research. ;Copyright American Association for Cancer Research Inc Apr 15, 2017 ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-16-1741 ;PMID: 27827313Full text available |
|
13 |
Material Type: Article
|
Scientists in the dark after French clinical trial proves fatalNature (London), 2016-01, Vol.529 (7586), p.263-264 [Peer Reviewed Journal]ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature.2016.19189 ;PMID: 26791697Full text available |
|
14 |
Material Type: Article
|
Clinical experiences with systemically administered siRNA-based therapeutics in cancerNature reviews. Drug discovery, 2015-12, Vol.14 (12), p.843-856 [Peer Reviewed Journal]COPYRIGHT 2015 Nature Publishing Group ;Copyright Nature Publishing Group Dec 2015 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd4685 ;PMID: 26567702Full text available |
|
15 |
Material Type: Article
|
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer TherapyCancer cell, 2014-06, Vol.25 (6), p.846-859 [Peer Reviewed Journal]2014 Elsevier Inc. ;Copyright © 2014 Elsevier Inc. All rights reserved. ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccr.2014.05.016 ;PMID: 24898549Full text available |
|
16 |
Material Type: Article
|
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer ImmunotherapyJournal of clinical oncology, 2018-03, Vol.36 (9), p.850-858 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2017.75.1644 ;PMID: 29341833Full text available |
|
17 |
Material Type: Article
|
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of TrialsChest, 2017-08, Vol.152 (2), p.271-281 [Peer Reviewed Journal]Copyright © 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. ;EISSN: 1931-3543 ;DOI: 10.1016/j.chest.2017.04.177 ;PMID: 28499515Full text available |
|
18 |
Material Type: Article
|
Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative designClinical cancer research, 2014-09, Vol.20 (18), p.4758-4767 [Peer Reviewed Journal]2014 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-13-2671 ;PMID: 25037736Full text available |
|
19 |
Material Type: Article
|
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapyNature (London), 2016-06, Vol.534 (7607), p.396-401 [Peer Reviewed Journal]COPYRIGHT 2016 Nature Publishing Group ;COPYRIGHT 2016 Nature Publishing Group ;Copyright Nature Publishing Group Jun 16, 2016 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature18300 ;PMID: 27281205 ;CODEN: NATUASFull text available |
|
20 |
Material Type: Article
|
Antibody Drug Conjugates for Cancer TherapyPharmacological reviews, 2016-01, Vol.68 (1), p.3-19 [Peer Reviewed Journal]Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics. ;ISSN: 0031-6997 ;EISSN: 1521-0081 ;DOI: 10.1124/pr.114.009373 ;PMID: 26589413Full text available |